93M-21986-04648
2 vaccinations
1 coded response
3 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 432 / OH
- Registered
- 2021-03-07
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-04
Dose 1 — Pfizer-BioNTech
-
2021-03-07
Registered in v-safe
- 2021-03-07
-
2021-03-25
Dose 2 — Pfizer-BioNTech
- 2021-03-31
-
2022-03-25
Survey response — 12 months, dose 2MedDRA: Ageusia, Anosmia, COVID-19, Cough, Headache, Nasal discomfort, Nausea, Respiratory tract congestion — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Covid in January - headache, congestion, cough, loss of taste and smell, nausea, nasal burning (did not have fever or sore throat)MedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-04 | Pfizer-BioNTech | |
| 2 | 2021-03-25 | Pfizer-BioNTech |
Free text
Release 11 — 12 months, dose 2
Symptoms: Covid in January - headache, congestion, cough, loss of taste and smell, nausea, nasal burning (did not have fever or sore throat)
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Ageusia | · | · | ✓ |
| SD | Anosmia | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Nasal discomfort | · | · | ✓ |
| SD | Nausea | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release